default author photo

Maya Hites

Université Libre de Bruxelles (ULB)

SCHOLARLY PAPERS

3

DOWNLOADS

442

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Effects of Remdesivir in Hospitalized Patients with COVID-19: Systematic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials

Number of pages: 32 Posted: 11 Oct 2022
Basel University - CLEAR Methods Center, University of Basel - University Hospital Basel, Hôpital Bichat, APHP, University of Oslo - Oslo University Hospital, University of Paris, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Hôpital Bichat, APHP, University of British Columbia (UBC), University of North Carolina (UNC) at Chapel Hill - National Institute of Health, Government of the People's Republic of China - Department of Pulmonary and Critical Care Medicine, Helsinki University Hospital, Hospices Civils de Lyon - Département des Maladies Infectieuses et Tropicales, Université Libre de Bruxelles (ULB), University of Claude Bernard Lyon 1, Hospices Civils de Lyon - Laboratoire de Virologie, University of Toronto, McGill University - Division of Experimental Medicine, University of Toronto - Sunnybrook Health Sciences Centre, University of Oslo - Oslo University Hospital, University of Oslo - Department of Immunology and Transfusion Medicine, University of Oslo - Oslo University Hospital, affiliation not provided to SSRN, China-Japan Friendship Hospital - Department of Pulmonary and Critical Care Medicine, University of North Carolina (UNC) at Chapel Hill - National Institute of Health, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - Basel Institute for Clinical Epidemiology and Biostatistics, University of Basel - University Hospital Basel, Hôpital Bichat - Claude-Bernard - INSERM, IAME Infectious Diseases Department, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Oslo - Oslo University Hospital and University of Basel - University Hospital Basel
Downloads 191 (399,431)

Abstract:

Loading...

Remdesivir, COVID-19, systematic review, individual patient data meta analysis, randomized controlled trials, GS-5734

2.

Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial

Number of pages: 34 Posted: 03 Aug 2022
University of Oslo - Section for Clinical Immunology and Infectious Diseases, Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, University of Oslo - Institute of Clinical Medicine, University of Lille, affiliation not provided to SSRN, University of Verona, Hospital Universitario Virgen Macarena - Unidad Clínica de Enfermedades Infecciosas, affiliation not provided to SSRN, Université Libre de Bruxelles (ULB), Medical University of Innsbruck, Government of Portugal - Unidade Local de Saúde de São João, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, Sorbonne University, University of Oslo - Division of Emergencies and Critical Care, University of Claude Bernard Lyon 1, affiliation not provided to SSRN, University of Pécs, National and Kapodistrian University of Athens, University Hospital Brno, University of Basel - University Hospital Basel, Hacettepe University, Technische Universität München (TUM), Hospices Civils de Lyon - Département des Maladies Infectieuses et Tropicales, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Oslo - Oslo University Hospital, Sorbonne University, University of Oslo - Oslo University Hospital, affiliation not provided to SSRN, Vestre Viken Hospital Trust, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, University of Oslo - Institute of Clinical Medicine, University of Stavanger - Stavanger University Hospital, Hospital Universitario La Paz, Vestre Viken Hospital Trust, University Hospital North Norway, Hospices Civils de Lyon - Service de Médecine Intensive-Réanimation, Akershus University Hospital - Department of Infectious Diseases, Norwegian Institute of Public Health, Sorbonne University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oslo - Department of Immunology and Transfusion Medicine, Hospices Civils de Lyon - Laboratoire de Virologie, University of Nantes - INSERM, University of Oslo - Oslo University Hospital, Norwegian Institute of Public Health, University of Verona - Infectious Diseases, Department of Diagnostic and Public Health, affiliation not provided to SSRN, University of Oslo - Department of Research Support for Clinical Trials and Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP
Downloads 176 (428,796)

Abstract:

Loading...

COVID-19, immunomodulator, safety, baricitinib, JAK inhibitor

3.

Humoral Immune Response Against SARS-CoV-2 after Adapted Covid-19 Vaccine Schedules in Healthy Adults: The IMCOVAS Study

Number of pages: 43 Posted: 09 Feb 2024
University of Antwerp, University of Antwerp, Hasselt University - Data Science Institute, Sciensano, Université Libre de Bruxelles (ULB) - ULB Center for Research in Immunology (U-CRI), University of Antwerp - Department of Clinical Sciences, University of Liège, University of Antwerp - Department of Clinical Sciences, Ghent University - Ghent University Hospital, Université Libre de Bruxelles (ULB), University of Tübingen - Institute of Tropical Medicine, University of Antwerp - Centre for Evaluation of Vaccination (CEV) and University of Antwerp - Vaccine and Infectious Disease Institute
Downloads 75 (867,774)

Abstract:

Loading...

anti-RBD IgG, Avidity, COVID-19, Humoral immunity, Immunogenicity, neutralizing antibodies, Sars-CoV-2, Vaccination, Vaccine schedule